Trial
NCT03491150
An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Alzheimer's Disease
Intervention
Crenezumab
Why stopped
This study was discontinued due to an interim analysis in the BN29552 study, which indicated that Crenezumab was unlikely to meet its primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-13